AGEN250117C2000
- 0.95
- 0.000.00%
Agenus Newsroom
Express News | Agenus Announced Five Presentations Featuring Botensilimab (Bot, An Fc-enhanced Anti-CTLA-4 Antibody) Plus Balstilimab (Bal, An Anti-PD-1 Antibody) At The Upcoming American Society Of Clinical Oncology Gastrointestinal Cancers Symposium
H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating
Express News | HC Wainwright & Co. Reiterates Neutral on Agenusto Neutral
Agenus Announces Strategic Realignment
Express News | Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating, Maintains Target Price $7
Agenus Secures $22 Million Mortgage, Plans Operational Realignment; Shares Jump
Express News | Agenus Inc - Plan Includes 60% Reduction in Annual External Expenditures
Express News | Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Agenus (AGEN) and SAGE Therapeutics (SAGE)
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Cuts Target Price to $11
B. Riley Adjusts Agenus Price Target to $11 From $18, Maintains Buy Rating
Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround
Agenus | 10-Q: Q3 2024 Earnings Report
Agenus Is Maintained at Neutral by HC Wainwright & Co.
Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript
H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating, Cuts Target Price to $7
Agenus Misses Q3 Estimates
Agenus 3Q Loss/Shr $3.08 >AGEN
Insights Ahead: Agenus's Quarterly Earnings